Home » Stocks » CRL

Charles River Laboratories International, Inc. (CRL)

Stock Price: $278.89 USD 5.17 (1.89%)
Updated Jan 19, 2021 4:00 PM EST - Market closed
Market Cap 13.87B
Revenue (ttm) 2.82B
Net Income (ttm) 301.46M
Shares Out 49.70M
EPS (ttm) 6.00
PE Ratio 46.50
Forward PE 29.94
Dividend n/a
Dividend Yield n/a
Trading Day January 19
Last Price $278.89
Previous Close $273.72
Change ($) 5.17
Change (%) 1.89%
Day's Open 275.72
Day's Range 274.14 - 280.10
Day's Volume 376,014
52-Week Range 98.90 - 280.10

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 5 days ago

WILMINGTON, Mass. & SHANGHAI--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announced that it has entered into a strategic partnership with JADE Biomedical to expand global biologics capa...

24/7 Wall Street - 1 week ago

Increasingly, the Wall Street firms we cover are starting to agree that while the future for the U.S.

Other stocks mentioned: FCX, NOC, CTLT
Business Wire - 1 week ago

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL--Charles River Laboratories to present at J.P. Morgan Healthcare Conference

Business Wire - 2 weeks ago

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #acquisition--Charles River acquires Distributed Bio, a next-generation antibody discovery company, to establish a premier, large molecule discovery...

Business Wire - 2 months ago

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #earnings--Charles River Laboratories to present at upcoming conferences

Seeking Alpha - 2 months ago

Charles River reported Q3 2020 results that beat the top- and bottom-line estimates. Moreover, the company has beat analysts' earnings estimates in each of the last eight quarters. Charles Riv...

Zacks Investment Research - 2 months ago

Charles River (CRL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Investment Research - 2 months ago

Charles River (CRL) possesses solid growth attributes, which could help it handily outperform the market.

Seeking Alpha - 2 months ago

Charles River Laboratories International (CRL) CEO James Foster on Q3 2020 Results - Earnings Call Transcript

Seeking Alpha - 2 months ago

Charles River Laboratories International, Inc.'s (CRL) CEO James Foster On Q3 2020 Results - Quick Version Earnings Call Transcript

Business Wire - 2 months ago

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #earnings--Charles River Laboratories Announces Third-Quarter 2020 Results

Zacks Investment Research - 2 months ago

Coronavirus is going to affect the earnings results of healthcare players. While hospitals and health insurers might have suffered the COVID-19 impact, others providing virtual care and COVID-...

Other stocks mentioned: CHE, DVA, NVCR, UHS
Insider Monkey - 2 months ago

Is Charles River Laboratories International Inc. (NYSE:CRL) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the ...

Zacks Investment Research - 2 months ago

Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 2 months ago

Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Forbes - 2 months ago

After the broader markets closed yesterday sharply down, the indices were set to rise today amidst optimism on a stimulus package and strong earnings. For investors looking to make sense of th...

Other stocks mentioned: AAP, JCI, ORLY, TGT
Forbes - 3 months ago

Big economic data this week will be released, including housing market updates, the Conference Board's leading economic index, and the IHS Markit update on some of its indexes. For investors l...

Other stocks mentioned: CMC, MCD, NSP, RSG
Business Wire - 3 months ago

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #boardofdirectors--Charles River Laboratories appoints George Llado, Senior Vice President and Chief Information Officer of Alexion Pharmaceuticals,...

Business Wire - 3 months ago

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #earnings--Charles River Laboratories Schedules Third-Quarter 2020 Earnings Release and Conference Call

Forbes - 3 months ago

Sentiment at the end of last week was wrought with uncertainty as President Trump tested positive for COVID-19, amidst the already tense economic and political situation. For investors looking...

Other stocks mentioned: AKAM, EPAM, LEN, SNPS
24/7 Wall Street - 4 months ago

The firms that we cover on Wall Street increasingly are starting to agree that the volatility the stock market is encountering now, and the beating the economy has taken this year, should cont...

Other stocks mentioned: GILD, HZNP, IGMS
Investors Business Daily - 4 months ago

Stocks Hit Resistance; Taiwan Semi, Horizon, Charles River Break Out

Stocks Hit Resistance; Taiwan Semi, Horizon Therapeutics, Charles River break out.

Other stocks mentioned: TSM, HZNP
Business Wire - 4 months ago

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #earnings--Charles River Laboratories to present at September investor conferences

Forbes - 5 months ago

The Dow opened 100 points higher backed up by financial stocks and value plays as strong results for Target and Lowe’s gave an indication that retail sales are back on track. Using our deep le...

Other stocks mentioned: FMC, ITT, PWR, SNPS
Forbes - 5 months ago

In Washington, it seems unlikely that the stimulus package would be agreed to in August at this point and could dampen the spirits of investors going forward if nothing is agreed to. Our deep ...

Other stocks mentioned: AME, GPI, PLAB, SPWH
Seeking Alpha - 5 months ago

Charles River Laboratories International, Inc. (CRL) CEO James Foster on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Charles River (CRL) delivered earnings and revenue surprises of 24.41% and 7.41%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 5 months ago

Shares of Charles River (NYSE:CRL) moved higher by 0.1% in pre-market trading after the company reported Q2 results.

Business Wire - 5 months ago

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #earnings--Charles River Laboratories Announces Second-Quarter 2020 Results

Zacks Investment Research - 5 months ago

Charles River Laboratories (CRL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Investment Research - 5 months ago

Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Investors Business Daily - 5 months ago

Charles River Labs International is in a potential buy area with earnings on tap for Aug. 5. The stock is approximately 2% above a 189.95 buy point from a second-stage.

Zacks Investment Research - 7 months ago

Charles River Laboratories International, Inc. (CRL) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover...

Zacks Investment Research - 7 months ago

As of late, it has definitely been a great time to be an investor in Charles River Laboratories.

Seeking Alpha - 8 months ago

Charles River Laboratories International, Inc. (CRL) CEO Jim Foster on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Charles River (CRL) delivered earnings and revenue surprises of 24.32% and 2.07%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 8 months ago

Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CNBC Television - 9 months ago

Distributed Bio CEO on developing therapeutic antibody treatment against coronavirus

CNBC's "Squawk on the Street" team discusses the possibility of a coronavirus cure with Jake Glanville, CEO of Distributed Bio.

Other stocks mentioned: PFE
Zacks Investment Research - 11 months ago

Does Charles River Laboratories (CRL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research - 11 months ago

Charles River (CRL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

CNBC Television - 11 months ago

Charles River Laboratories CEO: Biotech companies are 'growing exponentially

CNBC's Jim Cramer chats with Charles River Laboratories CEO Jim Foster to get a read on the drug research and evelopment landscape and the company's plans in China.

Seeking Alpha - 11 months ago

Charles River Laboratories International's (CRL) CEO Jim Foster on Q4 2019 Results -Earnings Call Transcript

Zacks Investment Research - 11 months ago

Charles River (CRL) delivered earnings and revenue surprises of 9.84% and 0.94%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 11 months ago

If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.

Other stocks mentioned: CDNS, MSFT, MXIM, RMD, RUTH
Zacks Investment Research - 11 months ago

Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 11 months ago

Growth at a reasonable price or GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount.

Other stocks mentioned: CDNS, ICLR, TTC
Zacks Investment Research - 1 year ago

Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Seeking Alpha - 1 year ago

Charles River Laboratories: Headwinds Ahead But That's Okay

CNBC Television - 1 year ago

Charles River Labs CEO: We see high single-digit growth over five years

Jim Cramer checks in with Charles River Labs CEO James Foster to get a read on how the stock could get back on track in the future.

Seeking Alpha - 1 year ago

Charles River Laboratories International, Inc. (CRL) CEO Jim Foster on Q3 2019 Results - Earnings Call Transcript

About CRL

Charles River Laboratories International, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research a... [Read more...]

Industry
Diagnostics & Research
IPO Date
Jun 23, 2000
CEO
James Foster
Employees
17,100
Stock Exchange
NYSE
Ticker Symbol
CRL
Full Company Profile

Financial Performance

In 2019, CRL's revenue was $2.62 billion, an increase of 15.67% compared to the previous year's $2.27 billion. Earnings were $252.02 million, an increase of 11.33%.

Financial Statements

Analyst Forecasts

According to 17 analysts, the average rating for CRL stock is "Buy." The 12-month stock price forecast is 265.71, which is a decrease of -4.73% from the latest price.

Price Target
$265.71
(-4.73% downside)
Analyst Consensus: Buy